Table 3.
Subgroup and Meta-regression analysis of VAI in the diagnosis of MAFLD in included studies
| Subgroup | Number of studies | Sen(95%CI) | Spe(95%CI) | PLR(95%CI) | NLP(95%CI) | DOR(95%CI) | RDOR(95%CI) | P |
|---|---|---|---|---|---|---|---|---|
| Diagnostic methods | ||||||||
| Biopsy | 2[11, 18] | 0.79(0.74–0.83) | 0.84(0.76–0.89) | 5.00(1.27–19.72) | 0.24(0.19–0.30) | 19.79(4.8-81.63) | 4.06(1.87–8.79) | 0.0036 |
| Imaging examination | 7[10, 12–17] | 0.70(0.69–0.70) | 0.67(0.67–0.68) | 1.99(1.80–2.19) | 0.43(0.39–0.47) | 4.96(4.26–5.79) | ||
| Control source | ||||||||
| Healthy | 2[10, 18] | 0.78(0.68–0.85) | 0.72(0.64–0.79) | 2.75(2.06–3.67) | 0.31(0.21–0.46) | 8.78(4.76–16.06) | 1.38(0.35–5.40) | 0.5898 |
| Non-MAFLD | 7[11–17] | 0.70(0.69–0.70) | 0.67(0.67–0.68) | 2.01(1.80–2.25) | 0.39(0.35–0.45) | 5.55(4.48–6.88) | ||
| Race | ||||||||
| Asian | 3[12, 16, 17] | 0.70(0.69–0.70) | 0.67(0.67–0.68) | 2.04(1.86–2.24) | 0.43(0.39–0.48) | 4.84(4.07–5.75) | 1.70(0.69–4.22) | 0.2091 |
| European | 6[10, 11, 13–15, 18] | 0.76(0.72–0.79) | 0.67(0.64–0.71) | 2.66(1.61–4.38) | 0.33(0.24–0.45) | 8.39(4.38–16.05) | ||
Abbreviations: Sen Sensitivity Spe Specificity, PLR Positive likelihood ratio, NLR Negative likelihood ratio, DOR Diagnostic odds ratio, RDOR Relative diagnostic odds ratio, MAFLD metabolic-associated fatty liver disease
The P value represents the statistical difference of DOR between different groups